Skip to main content

Advertisement

Figure 4 | Journal of Neuroinflammation

Figure 4

From: Fractalkine (CX3CL1) enhances hippocampal N-methyl-d-aspartate receptor (NMDAR) function via d-serine and adenosine receptor type A2 (A2AR) activity

Figure 4

The absence of adenosine receptor type A2 (A 2A R) prevents CX 3 CL1 action. Graphs represent the average timecourse of CX3CL1 effects on N-methyl-d-aspartate receptor component of field excitatory postsynaptic potentials (NMDA-fEPSPs). Points: mean ± SEM. Horizontal bar, CX3CL1 application (5 nM). (A) In A1R−/− mice, application of CX3CL1 enhanced NMDA-fEPSPs (n = 10/3). (B) The absence of A3R did not interfere with CX3CL1 action (n = 10/2). (C) In A2AR−/− mice, CX3CL1 was ineffective (n = 11/3).

Back to article page